<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01605994</url>
  </required_header>
  <id_info>
    <org_study_id>CN171-002</org_study_id>
    <nct_id>NCT01605994</nct_id>
  </id_info>
  <brief_title>Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-933043 in Healthy Subjects</brief_title>
  <official_title>Placebo-Controlled, Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-933043</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Includes a placebo-controlled sequential, ascending multiple-dose panels (10 panels, 8
      ascending doses, and 2 fixed Japanese Panels exploring safety, tolerability, and
      Pharmacokinetic (PK) measures
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of multiple oral doses of BMS-933043 in healthy subjects measured by AEs, Vital signs, clinical laboratory test results, physical examination findings, neurological examination findings and electrocardiogram (ECG) parameters</measure>
    <time_frame>Up to Day 26 of Follow-up</time_frame>
    <description>AEs = Adverse Events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>Day 1, Day 3, Day 6, Day 9, Day 10, Day 11 and Day 12</time_frame>
    <description>PK of BMS-933043, BMS-941651, BMS-972869 and BMS-610999 will be derived from plasma concentration versus time and urinary excretion data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed plasma concentration (Tmax)</measure>
    <time_frame>Day 1, Day 3, Day 6, Day 9, Day 10, Day 11 and Day 12</time_frame>
    <description>PK of BMS-933043, BMS-941651, BMS-972869 and BMS-610999 will be derived from plasma concentration versus time and urinary excretion data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve in one dosing interval [AUC(TAU)]</measure>
    <time_frame>Day 1, Day 3, Day 6, Day 9, Day 10, Day 11 and Day 12</time_frame>
    <description>PK of BMS-933043, BMS-941651, BMS-972869 and BMS-610999 will be derived from plasma concentration versus time and urinary excretion data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma half-life (T-HALF)</measure>
    <time_frame>Day 1, Day 3, Day 6, Day 9, Day 10, Day 11 and Day 12</time_frame>
    <description>PK of BMS-933043, BMS-941651, BMS-972869 and BMS-610999 will be derived from plasma concentration versus time and urinary excretion data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough observed plasma concentration (Cmin) between dose interval</measure>
    <time_frame>Day 1, Day 3, Day 6, Day 9, Day 10, Day 11 and Day 12</time_frame>
    <description>PK of BMS-933043, BMS-941651, BMS-972869 and BMS-610999 will be derived from plasma concentration versus time and urinary excretion data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady-state (VSS/F) of BMS-933043</measure>
    <time_frame>Day 1, Day 3, Day 6, Day 9, Day 10, Day 11 and Day 12</time_frame>
    <description>PK of BMS-933043 will be derived from plasma concentration versus time and urinary excretion data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation index (AI): ratio of AUC(TAU) at steady-state to AUC(TAU) after the first dose</measure>
    <time_frame>Day 1, Day 3, Day 6, Day 9, Day 10, Day 11 and Day 12</time_frame>
    <description>PK of BMS-933043, BMS-941651, BMS-972869 and BMS-610999 will be derived from plasma concentration versus time and urinary excretion data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of metabolite AUC(TAU) to parent AUC(TAU), corrected for molecular weight [MR AUC(tau)]</measure>
    <time_frame>Day 1, Day 3, Day 6, Day 9, Day 10, Day 11 and Day 12</time_frame>
    <description>PK of BMS-933043, BMS-941651, BMS-972869 and BMS-610999 will be derived from plasma concentration versus time and urinary excretion data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of metabolite Cmax to parent Cmax, corrected for molecular weight [MR Cmax]</measure>
    <time_frame>Day 1, Day 3, Day 6, Day 9, Day 10, Day 11 and Day 12</time_frame>
    <description>PK of BMS-933043, BMS-941651, BMS-972869 and BMS-610999 will be derived from plasma concentration versus time and urinary excretion data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CSF penetration of BMS-933043</measure>
    <time_frame>Day 8</time_frame>
    <description>Cerebral Spinal Fluid (CSF) will be analyzed for drug levels to confirm adequate central nervous system (CNS) penetration (&gt;2 nM is required) and to estimate the brain/plasma ratio in humans</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of BMS-933043 on ECG intervals and to explore the relationship between plasma exposure and ECG intervals</measure>
    <time_frame>Baseline (Day -2), Day 1, Day 6 and Day 10</time_frame>
    <description>The effects of BMS-933043 on ECG parameters (heart rate, QTcF, PR, and QRS) will be explored graphically and by summary statistics. Absolute levels, as well as changes from baseline, will be summarized and plotted versus time by treatment and day for each ECG parameter. Frequency distributions for subjects' maximum values will be provided by treatment. The relationships between ECG parameters and BMS-933043 concentrations may be explored using scatter plots and the relationship between the change from baseline in QTcF and the BMS-933043 concentration may be estimated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of multiple oral doses of BMS-9333043 in Japanese healthy subjects is measured by AEs, Vital signs, clinical laboratory test results, physical examination findings, neurological examination findings and ECG parameters</measure>
    <time_frame>Up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of ethnicity (Japanese versus non-Japanese) on PK of BMS-933043 will be assessed graphically and by point estimates and 90% confidence intervals for geometric mean ratio for Cmax using data from subjects receiving the same dose of BMS-933043</measure>
    <time_frame>Day 1, Day 3, Day 6, Day 9, Day 10, Day 11 and Day 12</time_frame>
  </secondary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Actual">115</enrollment>
  <condition>Healthy Adult Normals</condition>
  <arm_group>
    <arm_group_label>Panel 1:BMS-933043(2mg)/Placebo+Antacid Buffer Solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-933043 2 mg solution by mouth twice daily for 10 days
OR
Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days
Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 2:BMS-933043(5mg)/Placebo+Antacid Buffer Solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-933043 5 mg solution by mouth twice daily for 10 days
OR
Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days
Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 3:BMS-933043(10mg)/Placebo+Antacid Buffer Solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-933043 10 mg solution by mouth twice daily for 10 days
OR
Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days
Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 4:BMS-933043(25mg)/Placebo+Antacid Buffer Solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-933043 25 mg solution by mouth twice daily for 10 days
OR
Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days
Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 5:BMS-933043(50mg)/Placebo+Antacid Buffer Solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-933043 50 mg solution by mouth twice daily for 10 days
OR
Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days
Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days
CSF sampling required</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 6:BMS-933043(100mg)/Placebo+Antacid Buffer Solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-933043 100 mg solution by mouth twice daily for 10 days
OR
Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days
Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 7:BMS-933043(200mg)/Placebo+Antacid Buffer Solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-933043 200 mg solution by mouth twice daily for 10 days
OR
Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days
Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 8:BMS-933043(25mg)/Placebo+Antacid Buffer Predose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MAD Phase: Japanese Subjects. Cerebrospinal fluid (CSF) sampling not required
BMS-933043 25 mg solution by mouth twice daily for 10 days
OR
Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days
Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 9:BMS-933043(200mg)/Placebo+Antacid Buffer Predose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Japanese Subjects. CSF sampling not required.
BMS-933043 200 mg solution by mouth twice daily for 10 days
OR
Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days
Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 10:BMS-933043(350mg)/Placebo+Antacid Buffer Predose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-933043 350 mg solution by mouth twice daily for 10 days
OR
Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days
Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CSF Panel:BMS-933043(MTD)/Placebo+Antacid Buffer Predose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>If Panel 5 does not run. CSF Sampling at steady state
BMS-933043 maximum tolerated dose (MTD), solution by mouth twice daily for 10 days
OR
Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days
Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-933043</intervention_name>
    <arm_group_label>Panel 1:BMS-933043(2mg)/Placebo+Antacid Buffer Solution</arm_group_label>
    <arm_group_label>Panel 2:BMS-933043(5mg)/Placebo+Antacid Buffer Solution</arm_group_label>
    <arm_group_label>Panel 3:BMS-933043(10mg)/Placebo+Antacid Buffer Solution</arm_group_label>
    <arm_group_label>Panel 4:BMS-933043(25mg)/Placebo+Antacid Buffer Solution</arm_group_label>
    <arm_group_label>Panel 5:BMS-933043(50mg)/Placebo+Antacid Buffer Solution</arm_group_label>
    <arm_group_label>Panel 6:BMS-933043(100mg)/Placebo+Antacid Buffer Solution</arm_group_label>
    <arm_group_label>Panel 7:BMS-933043(200mg)/Placebo+Antacid Buffer Solution</arm_group_label>
    <arm_group_label>Panel 8:BMS-933043(25mg)/Placebo+Antacid Buffer Predose</arm_group_label>
    <arm_group_label>Panel 9:BMS-933043(200mg)/Placebo+Antacid Buffer Predose</arm_group_label>
    <arm_group_label>Panel 10:BMS-933043(350mg)/Placebo+Antacid Buffer Predose</arm_group_label>
    <arm_group_label>CSF Panel:BMS-933043(MTD)/Placebo+Antacid Buffer Predose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo matching with BMS-933043</intervention_name>
    <arm_group_label>Panel 1:BMS-933043(2mg)/Placebo+Antacid Buffer Solution</arm_group_label>
    <arm_group_label>Panel 2:BMS-933043(5mg)/Placebo+Antacid Buffer Solution</arm_group_label>
    <arm_group_label>Panel 3:BMS-933043(10mg)/Placebo+Antacid Buffer Solution</arm_group_label>
    <arm_group_label>Panel 4:BMS-933043(25mg)/Placebo+Antacid Buffer Solution</arm_group_label>
    <arm_group_label>Panel 5:BMS-933043(50mg)/Placebo+Antacid Buffer Solution</arm_group_label>
    <arm_group_label>Panel 6:BMS-933043(100mg)/Placebo+Antacid Buffer Solution</arm_group_label>
    <arm_group_label>Panel 7:BMS-933043(200mg)/Placebo+Antacid Buffer Solution</arm_group_label>
    <arm_group_label>Panel 8:BMS-933043(25mg)/Placebo+Antacid Buffer Predose</arm_group_label>
    <arm_group_label>Panel 9:BMS-933043(200mg)/Placebo+Antacid Buffer Predose</arm_group_label>
    <arm_group_label>Panel 10:BMS-933043(350mg)/Placebo+Antacid Buffer Predose</arm_group_label>
    <arm_group_label>CSF Panel:BMS-933043(MTD)/Placebo+Antacid Buffer Predose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antacid Buffer Predose Solution</intervention_name>
    <arm_group_label>Panel 1:BMS-933043(2mg)/Placebo+Antacid Buffer Solution</arm_group_label>
    <arm_group_label>Panel 2:BMS-933043(5mg)/Placebo+Antacid Buffer Solution</arm_group_label>
    <arm_group_label>Panel 3:BMS-933043(10mg)/Placebo+Antacid Buffer Solution</arm_group_label>
    <arm_group_label>Panel 4:BMS-933043(25mg)/Placebo+Antacid Buffer Solution</arm_group_label>
    <arm_group_label>Panel 5:BMS-933043(50mg)/Placebo+Antacid Buffer Solution</arm_group_label>
    <arm_group_label>Panel 6:BMS-933043(100mg)/Placebo+Antacid Buffer Solution</arm_group_label>
    <arm_group_label>Panel 7:BMS-933043(200mg)/Placebo+Antacid Buffer Solution</arm_group_label>
    <arm_group_label>Panel 8:BMS-933043(25mg)/Placebo+Antacid Buffer Predose</arm_group_label>
    <arm_group_label>Panel 9:BMS-933043(200mg)/Placebo+Antacid Buffer Predose</arm_group_label>
    <arm_group_label>Panel 10:BMS-933043(350mg)/Placebo+Antacid Buffer Predose</arm_group_label>
    <arm_group_label>CSF Panel:BMS-933043(MTD)/Placebo+Antacid Buffer Predose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects as determined by no clinically significant deviation from normal
             medical history, physical examination, ECGs and clinical laboratory determinations

          -  Body Mass Index (BMI) of 18 to 30 kg/m2, inclusive. BMI = weight (kg)/ [height (m)]2

          -  Normal Neurological Exam (LP subjects only: to rule out focal CNS lesions that would
             render LP unsafe)

          -  Men and women, ages 18 to 55 years, inclusive.

          -  Women who are not of childbearing potential (WOCBP) [ie, who are postmenopausal or
             surgically sterile] and men

          -  Women must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L
             or equivalent units of HCG) within 24 hours prior to the start of investigational
             product.

          -  Women must not be breastfeeding

          -  Sexually active fertile men must use effective birth control if their partners are
             WOCBP throughout the study and for 90 days after last dose

        Exclusion Criteria:

          -  Any significant acute or chronic medical illness

          -  Current or recent (within 3 months of study drug administration) gastrointestinal
             disease

          -  Any major surgery within 4 weeks of study drug administration

          -  Any gastrointestinal surgery that could impact upon the absorption of study drug

          -  Donation of blood or plasma to a blood bank or in a clinical study (except a screening
             visit) within 4 weeks of study drug administration

          -  Blood transfusion within 4 weeks of study drug administration

          -  Inability to tolerate oral medication

          -  Inability to be venipunctured and/or tolerate venous access

          -  Smoking more than 1 cigarette/cigar per week, within 3 months prior to screening

          -  Regular daily use of nicotine products or Varenicline (Chantix® or Champix®) within 3
             months prior to screening

          -  Recent (within 6 months of study drug administration) drug or alcohol abuse as defined
             in Diagnostic and Statistical Manual of Mental Disorders (4th Edition) [DSM IV],
             Diagnostic Criteria for Drug and Alcohol Abuse

          -  History of cardiac arrhythmias, or palpitations associated with presyncope or syncope
             or history of unexplained syncope
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinilabs, Inc.</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2012</study_first_submitted>
  <study_first_submitted_qc>May 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2012</study_first_posted>
  <last_update_submitted>June 26, 2014</last_update_submitted>
  <last_update_submitted_qc>June 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Antacids</mesh_term>
    <mesh_term>Anti-Ulcer Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

